Eli Lilly announced a major manufacturing push in East Asia, earmarking roughly $3 billion over the next decade to expand oral solid‑dose capacity in China to support the launch of its GLP‑1 candidate orforglipron and related programs. The company also pledged $500 million to bolster South Korea’s biopharma sector, signaling dual supply‑chain and market commitments. Lilly framed the investments as strategic moves to secure supply ahead of expected global demand for obesity and metabolic medicines. The capital will fund new facilities, scale production and strengthen local supply chains in regions already attracting pharma manufacturing expansion.